Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash & Equivalents data on file, last reported at $62.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $62.1 million, down 41.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.1 million (down 41.43% YoY), and the FY2025 annual result was $54.3 million, down 39.08% from the prior year.
• Cash & Equivalents grew to $62.1 million in Q1 2026 per RYTM's latest filing, from $54.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $185.4 million in Q3 2022 and troughed at $48.0 million in Q3 2024.
• A 5-year average of $95.4 million and a median of $89.1 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 114.86% in 2022, then slumped 64.99% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $128.0 million in 2022, then tumbled by 52.81% to $60.4 million in 2023, then soared by 47.56% to $89.1 million in 2024, then tumbled by 39.08% to $54.3 million in 2025, then grew by 14.43% to $62.1 million in 2026.
• Business Quant data shows RYTM's Cash & Equivalents at $62.1 million in Q1 2026, $54.3 million in Q4 2025, and $52.7 million in Q3 2025.